Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.10
CRL's Cash-to-Debt is ranked lower than
91% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.86 vs. CRL: 0.10 )
Ranked among companies with meaningful Cash-to-Debt only.
CRL' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04  Med: 0.3 Max: 15.68
Current: 0.1
0.04
15.68
Equity-to-Asset 0.31
CRL's Equity-to-Asset is ranked lower than
82% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. CRL: 0.31 )
Ranked among companies with meaningful Equity-to-Asset only.
CRL' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.3  Med: 0.51 Max: 0.72
Current: 0.31
-0.3
0.72
Interest Coverage 8.57
CRL's Interest Coverage is ranked lower than
73% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.70 vs. CRL: 8.57 )
Ranked among companies with meaningful Interest Coverage only.
CRL' s Interest Coverage Range Over the Past 10 Years
Min: 4.09  Med: 8.2 Max: 14.87
Current: 8.57
4.09
14.87
Piotroski F-Score: 4
Altman Z-Score: 2.48
Beneish M-Score: -2.48
WACC vs ROIC
8.19%
9.31%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 14.12
CRL's Operating Margin % is ranked higher than
81% of the 166 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.66 vs. CRL: 14.12 )
Ranked among companies with meaningful Operating Margin % only.
CRL' s Operating Margin % Range Over the Past 10 Years
Min: -33.48  Med: 14.3 Max: 18.46
Current: 14.12
-33.48
18.46
Net Margin % 9.20
CRL's Net Margin % is ranked higher than
79% of the 165 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.76 vs. CRL: 9.20 )
Ranked among companies with meaningful Net Margin % only.
CRL' s Net Margin % Range Over the Past 10 Years
Min: -38.84  Med: 9.4 Max: 12.55
Current: 9.2
-38.84
12.55
ROE % 19.11
CRL's ROE % is ranked higher than
87% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.21 vs. CRL: 19.11 )
Ranked among companies with meaningful ROE % only.
CRL' s ROE % Range Over the Past 10 Years
Min: -34.11  Med: 16.92 Max: 21.25
Current: 19.11
-34.11
21.25
ROA % 6.27
CRL's ROA % is ranked higher than
74% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. CRL: 6.27 )
Ranked among companies with meaningful ROA % only.
CRL' s ROA % Range Over the Past 10 Years
Min: -21.02  Med: 6.29 Max: 7.58
Current: 6.27
-21.02
7.58
ROC (Joel Greenblatt) % 28.62
CRL's ROC (Joel Greenblatt) % is ranked higher than
70% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. CRL: 28.62 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CRL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -50.32  Med: 19.05 Max: 32.31
Current: 28.62
-50.32
32.31
3-Year Revenue Growth Rate 13.40
CRL's 3-Year Revenue Growth Rate is ranked higher than
78% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.30 vs. CRL: 13.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CRL' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -17.6  Med: 7 Max: 13.4
Current: 13.4
-17.6
13.4
3-Year EBITDA Growth Rate 14.20
CRL's 3-Year EBITDA Growth Rate is ranked higher than
69% of the 130 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.40 vs. CRL: 14.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CRL' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -18.2  Med: 8.15 Max: 25.2
Current: 14.2
-18.2
25.2
3-Year EPS without NRI Growth Rate 14.40
CRL's 3-Year EPS without NRI Growth Rate is ranked higher than
69% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.20 vs. CRL: 14.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CRL' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -29.4  Med: 9.35 Max: 43.3
Current: 14.4
-29.4
43.3
GuruFocus has detected 3 Warning Signs with Charles River Laboratories International Inc $CRL.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CRL's 10-Y Financials

Financials (Next Earnings Date: 2017-05-14 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

CRL Guru Trades in Q1 2016

David Dreman 57,090 sh (New)
Joel Greenblatt 70,227 sh (New)
Robert Olstein 24,286 sh (New)
Paul Tudor Jones 264,559 sh (+1200.94%)
Jim Simons 950,209 sh (+8.91%)
Ken Fisher 529,834 sh (+2.58%)
Pioneer Investments 293,498 sh (+0.39%)
Westport Asset Management 155,000 sh (unchged)
Ray Dalio Sold Out
John Rogers 1,666,955 sh (-4.36%)
PRIMECAP Management 1,213,160 sh (-4.58%)
Steven Cohen 104,600 sh (-19.23%)
» More
Q2 2016

CRL Guru Trades in Q2 2016

Robert Olstein 55,901 sh (+130.18%)
David Dreman Sold Out
Steven Cohen Sold Out
Ken Fisher 516,128 sh (-2.59%)
Westport Asset Management 150,000 sh (-3.23%)
Pioneer Investments 271,726 sh (-7.42%)
John Rogers 1,464,130 sh (-12.17%)
Jim Simons 780,109 sh (-17.90%)
PRIMECAP Management 970,660 sh (-19.99%)
Paul Tudor Jones 162,837 sh (-38.45%)
Joel Greenblatt 11,856 sh (-83.12%)
» More
Q3 2016

CRL Guru Trades in Q3 2016

Robert Olstein 85,625 sh (+53.17%)
Jim Simons 935,909 sh (+19.97%)
Pioneer Investments 297,709 sh (+9.56%)
Joel Greenblatt Sold Out
Ken Fisher 508,660 sh (-1.45%)
John Rogers 1,426,842 sh (-2.55%)
PRIMECAP Management 909,660 sh (-6.28%)
Paul Tudor Jones 8,900 sh (-94.53%)
» More
Q4 2016

CRL Guru Trades in Q4 2016

Joel Greenblatt 2,750 sh (New)
Robert Olstein 136,035 sh (+58.87%)
Jim Simons 1,120,209 sh (+19.69%)
John Rogers 1,576,856 sh (+10.51%)
Ken Fisher 490,104 sh (-3.65%)
PRIMECAP Management 875,000 sh (-3.81%)
Paul Tudor Jones 8,520 sh (-4.27%)
Pioneer Investments 164,423 sh (-44.77%)
» More
» Details

Insider Trades

Latest Guru Trades with CRL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 541711    SIC: 8732
Compare:NAS:ICLR, NAS:BRKR, NAS:VWR, NAS:PRAH, OTCPK:CZMWY, NYSE:ALR, NAS:PRXL, NYSE:BIO.B, NAS:NEOG, NAS:INCR, NAS:EXAS, NYSE:PKI, NAS:QGEN, NAS:DXCM, NAS:MYGN, OTCPK:ERFSF, NAS:AXDX, NAS:FMI, NAS:VREX, NAS:MEDP » details
Traded in other countries:RV6.Germany,
Charles River Laboratories International Inc provides research models and services required to enable in vivo drug discovery and development.

Charles River Laboratories is a leading provider of drug discovery and development services. With roughly 50% of market share worldwide, the research model and services segment is the leading provider of animal models for laboratory testing. The remainder of Charles River's revenue comes from its preclinical services segment, which offers discovery, toxicology, pathology, and its manufacturing testing services to pharmaceutical, biotechnology, and device companies.

Guru Investment Theses on Charles River Laboratories International Inc

John Rogers Comments on Charles River Laboratories Intl - Jan 20, 2017

Other holdings underperformed. Scientific research firm Charles River Laboratories Intl, Inc. (NYSE:CRL) slid –8.58% due to contracting customer spending and a general downturn in health care stocks. Like other similar firms, Charles River expanded over the last 15 years to be able to handle peak medical research, but as drug companies scaled back, there was clearly overcapacity. The company’s drug discovery business is still a bit slack. That said, many health care stocks slid this quarter during a huge rotation to financials. We think the current issues are largely cyclical but the secular push toward solving medical problems through pharmaceuticals remains intact—a long-term tailwind for Charles River.



From John Rogers (Trades, Portfolio)' Ariel Fund fourth quarter 2016 commentary.



Check out John Rogers latest stock trades

Top Ranked Articles about Charles River Laboratories International Inc

John Rogers Comments on Charles River Laboratories Intl Guru stock highlight
Other holdings underperformed. Scientific research firm Charles River Laboratories Intl, Inc. (NYSE:CRL) slid –8.58% due to contracting customer spending and a general downturn in health care stocks. Like other similar firms, Charles River expanded over the last 15 years to be able to handle peak medical research, but as drug companies scaled back, there was clearly overcapacity. The company’s drug discovery business is still a bit slack. That said, many health care stocks slid this quarter during a huge rotation to financials. We think the current issues are largely cyclical but the secular push toward solving medical problems through pharmaceuticals remains intact—a long-term tailwind for Charles River. Read more...

Ratios

vs
industry
vs
history
PE Ratio 27.20
CRL's PE Ratio is ranked higher than
57% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.02 vs. CRL: 27.20 )
Ranked among companies with meaningful PE Ratio only.
CRL' s PE Ratio Range Over the Past 10 Years
Min: 8.58  Med: 24.55 Max: 95.66
Current: 27.2
8.58
95.66
Forward PE Ratio 17.48
CRL's Forward PE Ratio is ranked higher than
65% of the 46 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.83 vs. CRL: 17.48 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 27.29
CRL's PE Ratio without NRI is ranked higher than
57% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.50 vs. CRL: 27.29 )
Ranked among companies with meaningful PE Ratio without NRI only.
CRL' s PE Ratio without NRI Range Over the Past 10 Years
Min: 8.51  Med: 24.24 Max: 77.86
Current: 27.29
8.51
77.86
Price-to-Owner-Earnings 20.08
CRL's Price-to-Owner-Earnings is ranked higher than
69% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.06 vs. CRL: 20.08 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
CRL' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 10.56  Med: 23.2 Max: 323.25
Current: 20.08
10.56
323.25
PB Ratio 4.97
CRL's PB Ratio is ranked lower than
65% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.55 vs. CRL: 4.97 )
Ranked among companies with meaningful PB Ratio only.
CRL' s PB Ratio Range Over the Past 10 Years
Min: 0.75  Med: 3.02 Max: 6
Current: 4.97
0.75
6
PS Ratio 2.50
CRL's PS Ratio is ranked higher than
57% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. CRL: 2.50 )
Ranked among companies with meaningful PS Ratio only.
CRL' s PS Ratio Range Over the Past 10 Years
Min: 1.11  Med: 2.24 Max: 3.82
Current: 2.5
1.11
3.82
Price-to-Free-Cash-Flow 17.21
CRL's Price-to-Free-Cash-Flow is ranked higher than
62% of the 73 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.34 vs. CRL: 17.21 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
CRL' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.62  Med: 16.76 Max: 765.42
Current: 17.21
8.62
765.42
Price-to-Operating-Cash-Flow 14.03
CRL's Price-to-Operating-Cash-Flow is ranked higher than
58% of the 86 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.21 vs. CRL: 14.03 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CRL' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.79  Med: 12.43 Max: 20.15
Current: 14.03
4.79
20.15
EV-to-EBIT 21.05
CRL's EV-to-EBIT is ranked higher than
50% of the 101 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.46 vs. CRL: 21.05 )
Ranked among companies with meaningful EV-to-EBIT only.
CRL' s EV-to-EBIT Range Over the Past 10 Years
Min: -10.7  Med: 17.75 Max: 27.8
Current: 21.05
-10.7
27.8
EV-to-EBITDA 13.95
CRL's EV-to-EBITDA is ranked higher than
56% of the 108 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 16.84 vs. CRL: 13.95 )
Ranked among companies with meaningful EV-to-EBITDA only.
CRL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -16.5  Med: 12.05 Max: 16.8
Current: 13.95
-16.5
16.8
PEG Ratio 3.08
CRL's PEG Ratio is ranked higher than
50% of the 38 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.08 vs. CRL: 3.08 )
Ranked among companies with meaningful PEG Ratio only.
CRL' s PEG Ratio Range Over the Past 10 Years
Min: 1.08  Med: 2.6 Max: 3.28
Current: 3.08
1.08
3.28
Shiller PE Ratio 168.54
CRL's Shiller PE Ratio is ranked lower than
100% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 39.56 vs. CRL: 168.54 )
Ranked among companies with meaningful Shiller PE Ratio only.
CRL' s Shiller PE Ratio Range Over the Past 10 Years
Min: 90.11  Med: 158.52 Max: 1940.5
Current: 168.54
90.11
1940.5
Current Ratio 1.53
CRL's Current Ratio is ranked lower than
75% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. CRL: 1.53 )
Ranked among companies with meaningful Current Ratio only.
CRL' s Current Ratio Range Over the Past 10 Years
Min: 1.35  Med: 1.96 Max: 3.24
Current: 1.53
1.35
3.24
Quick Ratio 1.31
CRL's Quick Ratio is ranked lower than
73% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. CRL: 1.31 )
Ranked among companies with meaningful Quick Ratio only.
CRL' s Quick Ratio Range Over the Past 10 Years
Min: 0.97  Med: 1.65 Max: 2.79
Current: 1.31
0.97
2.79
Days Inventory 34.16
CRL's Days Inventory is ranked higher than
68% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.88 vs. CRL: 34.16 )
Ranked among companies with meaningful Days Inventory only.
CRL' s Days Inventory Range Over the Past 10 Years
Min: 33.43  Med: 41.32 Max: 49.49
Current: 34.16
33.43
49.49
Days Sales Outstanding 61.18
CRL's Days Sales Outstanding is ranked higher than
50% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 61.18 vs. CRL: 61.18 )
Ranked among companies with meaningful Days Sales Outstanding only.
CRL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 53.42  Med: 59.61 Max: 65.6
Current: 61.18
53.42
65.6
Days Payable 24.16
CRL's Days Payable is ranked lower than
84% of the 135 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 57.49 vs. CRL: 24.16 )
Ranked among companies with meaningful Days Payable only.
CRL' s Days Payable Range Over the Past 10 Years
Min: 14.93  Med: 15.77 Max: 24.16
Current: 24.16
14.93
24.16

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 0.10
CRL's 3-Year Average Share Buyback Ratio is ranked higher than
84% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.80 vs. CRL: 0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CRL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -62.6  Med: 0.3 Max: 10.3
Current: 0.1
-62.6
10.3

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.34
CRL's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
68% of the 76 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. CRL: 1.34 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
CRL' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.95  Med: 1.33 Max: 1.76
Current: 1.34
0.95
1.76
Price-to-Median-PS-Value 1.12
CRL's Price-to-Median-PS-Value is ranked lower than
56% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.03 vs. CRL: 1.12 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CRL' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.56  Med: 1.14 Max: 1.64
Current: 1.12
0.56
1.64
Price-to-Peter-Lynch-Fair-Value 3.09
CRL's Price-to-Peter-Lynch-Fair-Value is ranked lower than
60% of the 25 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.77 vs. CRL: 3.09 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
CRL' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 1.13  Med: 2.68 Max: 3.17
Current: 3.09
1.13
3.17
Earnings Yield (Greenblatt) % 4.77
CRL's Earnings Yield (Greenblatt) % is ranked higher than
77% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.78 vs. CRL: 4.77 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CRL' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.6  Med: 5.4 Max: 14.1
Current: 4.77
3.6
14.1
Forward Rate of Return (Yacktman) % 13.40
CRL's Forward Rate of Return (Yacktman) % is ranked higher than
64% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.41 vs. CRL: 13.40 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
CRL' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 2.8  Med: 5.6 Max: 22.3
Current: 13.4
2.8
22.3

More Statistics

Revenue (TTM) (Mil) $1,681
EPS (TTM) $ 3.23
Beta0.96
Short Percentage of Float4.12%
52-Week Range $67.20 - 91.57
Shares Outstanding (Mil)47.37

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 1,836 1,968 2,107
EPS ($) 5.08 5.62 5.91
EPS without NRI ($) 5.08 5.62 5.91
EPS Growth Rate
(Future 3Y To 5Y Estimate)
9.52%
Dividends per Share ($)
» More Articles for CRL

Headlines

Articles On GuruFocus.com
5 Best Stocks for Value Investors This Week - Feb. 25 Feb 26 2017 
John Rogers Comments on Charles River Laboratories Intl Jan 20 2017 
John Rogers' Ariel Fund 4th Quarter Commentary Jan 20 2017 
Bob Olstein's Olstein Strategic Opportunities Fund 2nd Quarter Commentary Sep 01 2016 
Olstein Strategic Opportunities Fund 1st Quarter Letter to Shareholders Jun 07 2016 
Olstein All Cap Value Fund First Quarter Commentary Jun 01 2016 
Weekly Highlight of CEO Sells Oct 13 2014 
John Rogers Comments on Charles River Laboratories Intl Inc Jul 22 2014 
John Rogers' Ariel Fund Second Quarter 2014 Commentary Jul 22 2014 
Robert Olstein’s Largest New Stock Picks Feb 12 2013 

More From Other Websites
Charles River Labs settles with feds over NIH billing flap Mar 14 2017
Company to pay $1.8M to settle claims of overbilling Mar 13 2017
Company to pay $1.8M to settle claims of overbilling Mar 13 2017
Charles River Laboratories and Chiesi Farmaceutici SpA Announce Extension of Integrated Respiratory... Mar 13 2017
Charles River Laboratories to Present at Raymond James and Barclays Conferences Mar 06 2017
CHARLES RIVER LABORATORIES INTERNATIONAL INC Financials Feb 18 2017
Charles River Laboratories International, Inc. :CRL-US: Earnings Analysis: 2016 By the Numbers :... Feb 16 2017
Charles River Laboratories International, Inc. :CRL-US: Earnings Analysis: Q4, 2016 By the Numbers :... Feb 15 2017
Edited Transcript of CRL earnings conference call or presentation 14-Feb-17 1:00pm GMT Feb 14 2017
Charles River Laboratories International Inc Earnings Call scheduled for 8:00 am ET today Feb 14 2017
Q4 2016 Charles River Laboratories International Inc Earnings Release - Before Market Open Feb 14 2017
CHARLES RIVER LABORATORIES INTERNATIONAL INC Files SEC form 8-K, Results of Operations and Financial... Feb 14 2017
Charles River tops Street 4Q forecasts Feb 14 2017
Charles River tops Street 4Q forecasts Feb 14 2017
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2016 Results from Continuing... Feb 14 2017
Healthcare Stock Q4 Earnings Slated for Feb 14: ESRX, CRL, Q Feb 13 2017
Charles River Laboratories Changes Time of Fourth-Quarter 2016 Earnings and 2017 Guidance Conference... Feb 09 2017
Charles River Laboratories Announces Progress Update for Collaboration with Moderna Therapeutics Jan 30 2017
John Rogers Comments on Charles River Laboratories Intl Jan 20 2017
John Rogers' Ariel Fund 4th Quarter Commentary Jan 20 2017
Charles River Laboratories Schedules Fourth-Quarter 2016 Earnings and 2017 Guidance Release and... Jan 19 2017
CHARLES RIVER LABORATORIES INTERNATIONAL INC Files SEC form 8-K, Results of Operations and Financial... Jan 10 2017
Charles River Laboratories to Present at J.P. Morgan Healthcare Conference Jan 09 2017
Charles River Laboratories International, Inc. breached its 50 day moving average in a Bullish... Dec 26 2016
Charles River Laboratories Demonstrates Expertise in CRISPR/Cas9 Genome Engineering Technology Dec 01 2016
Charles River Laboratories Presents Robust Program at Neuroscience 2016 Nov 10 2016
Charles River Announces Extension of Integrated Discovery Program with Genentech Oct 11 2016
Charles River Laboratories Schedules Third-Quarter 2016 Earnings Release and Conference Call Oct 06 2016
Charles River Laboratories Acquires Agilux Laboratories, Inc. Sep 28 2016
Charles River Laboratories and The Tri-Insitutional Therapeutics Discovery Institute Announce... Sep 22 2016
Charles River Laboratories to Present at September Investor Conferences Sep 06 2016
Charles River Laboratories Announces Partnership with the Milner Therapeutics Institute and... Aug 08 2016
Charles River Laboratories Announces Partnership with the Milner Therapeutics Institute and... Aug 08 2016
Charles River Laboratories Schedules Second-Quarter 2016 Earnings Release and Conference Call Jul 11 2016
Charles River Laboratories Acquires Blue Stream Laboratories Jun 27 2016
Charles River Laboratories to Present at Jefferies and William Blair Conferences Jun 06 2016
Moderna Therapeutics and Charles River Laboratories Announce Strategic Collaboration to Scale... Jun 06 2016
Charles River Laboratories and BioMotiv Enter into Strategic Partnership Apr 13 2016
Charles River Laboratories Schedules First-Quarter 2016 Earnings Release and Conference Call Apr 07 2016
Charles River Laboratories Completes the Acquisition of WIL Research Apr 04 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)